Enimmune corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, includ… Read more
Enimmune corporation (6564) - Total Liabilities
Latest total liabilities as of June 2025: NT$296.91 Million TWD
Based on the latest financial reports, Enimmune corporation (6564) has total liabilities worth NT$296.91 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enimmune corporation - Total Liabilities Trend (2019–2024)
This chart illustrates how Enimmune corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enimmune corporation Competitors by Total Liabilities
The table below lists competitors of Enimmune corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Leaders Technology Investment Co. Ltd
KQ:019570
|
Korea | ₩19.63 Billion |
|
Chang Jia M&E Engineering
TWO:4550
|
Taiwan | NT$715.58 Million |
|
Mentice AB
ST:MNTC
|
Sweden | Skr152.53 Million |
|
Malaysia Airport Holdings Bhd
KLSE:5014
|
Malaysia | RM11.84 Billion |
|
NextNRG Inc.
NASDAQ:NXXT
|
USA | $36.92 Million |
|
Asphere Innovations Public Company Limited
BK:AS
|
Thailand | ฿438.81 Million |
|
VPower Group International Holdings Limited
F:2V3
|
Germany | €3.95 Billion |
|
SAI.TECH Global Corporation
NASDAQ:SAI
|
USA | $1.26 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Enimmune corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enimmune corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enimmune corporation (2019–2024)
The table below shows the annual total liabilities of Enimmune corporation from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$244.49 Million | +40.95% |
| 2023-12-31 | NT$173.46 Million | +58.15% |
| 2022-12-31 | NT$109.68 Million | +173.95% |
| 2021-12-31 | NT$40.04 Million | -0.78% |
| 2020-12-31 | NT$40.35 Million | +606.20% |
| 2019-12-31 | NT$5.71 Million | -- |